Kiora Pharmaceuticals (KPRX) Return on Capital Employed (2017 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Return on Capital Employed came in at 65.24% in Q1 2026, down 2841.0% YoY from 2.38% in Q1 2025, and down 19.12% on a QoQ basis from 54.77% in Q4 2025.
Kiora Pharmaceuticals (KPRX) Return on Capital Employed (2017 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 10 years of Return on Capital Employed data on file, last reported at 65.24% in Q1 2026.
- Quarterly Return on Capital Employed fell 2841.0% year-over-year to 65.24% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 65.24% (down 2841.0% YoY) and the FY2025 annual result came in at 47.99%, down 7162.0% from the prior year.
- Return on Capital Employed declined to 65.24% in Q1 2026, from 54.77% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 14.32% in Q4 2024 to a low of 118.26% in Q3 2022.
- A 5-year average of 53.04% and a median of 65.24% in 2026 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed sank 7654 bps — and 2024, when it surged 10990 bps.
- Tracing KPRX's Return on Capital Employed over 5 years: stood at 82.63% in 2022, then retreated by 16 bps to 95.57% in 2023, then soared by 115 bps to 14.32% in 2024, then slumped by 482 bps to 54.77% in 2025, then fell by 19 bps to 65.24% in 2026.
- The last three Return on Capital Employed figures came in at 65.24% (Q1 2026), 54.77% (Q4 2025), and 28.55% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Kiora Pharmaceuticals | 15.64 Mn | 15.64 Mn | - | -63.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -63.72% |
| Mar 31, 2026 | -65.24% |
| Dec 31, 2025 | -54.77% |
| Sep 30, 2025 | -28.55% |
| Jun 30, 2025 | -36.56% |
| Mar 31, 2025 | -36.83% |
| Dec 31, 2024 | 14.32% |
| Sep 30, 2024 | 13.72% |
| Jun 30, 2024 | 6.60% |
| Mar 31, 2024 | 9.64% |
| Dec 31, 2023 | -95.57% |
| Sep 30, 2023 | -82.99% |
| Jun 30, 2023 | -66.70% |
| Mar 31, 2023 | -68.99% |
| Dec 31, 2022 | -82.63% |
| Sep 30, 2022 | -118.26% |
| Jun 30, 2022 | -112.30% |
| Mar 31, 2022 | -96.54% |
| Dec 31, 2021 | -67.14% |
| Sep 30, 2021 | -41.71% |